This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.
Sender's message:
Sent on Tuesday, 2011 Apr 19Search kinetoplastids OR kinetoplastid OR Kinetoplastida OR "trypanosoma brucei" OR leishmania OR brucei OR leishmaniasis OR "African trypanosomiasis"
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.
| PubMed Results |
| 1. | Parasitol Res. 2011 Apr 16. [Epub ahead of print]Mucosal Leishmania infantum infection.Richter J, Hanus I, Häussinger D, Löscher T, Harms G.Tropical Medicine Unit, Clinics for Gastroenterology, Hepatology and Infectious Diseases, University Clinics Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany, Joachim.Richter@med.uni-duesseldorf.de. AbstractMucosal leishmaniasis is a well-known clinical manifestation of infections caused by species belonging to the Leishmania (Viannia) subgenus in Central and South America but not of Leishmania species endemic in the so-called Old World. We report on three cases of mucosal leishmaniasis caused by Leishmania (Leishmania) infantum contracted in southern Europe. Two patients were immunocompromised; one patient had no underlying condition. Lesions were located in the oral mucosa, oesophagus and nose. All lesions relapsed under standard treatment with liposomal amphotericin B. A cure was achieved after secondary and extended treatment with liposomal amphotericin B or miltefosine. Mucosal leishmaniasis contracted in southern Europe has to be considered in the differential diagnosis of lesions in the naso-buccal-oesophageal mucosa and may occur in previously healthy persons. |
| PMID: 21499751 [PubMed - as supplied by publisher] | |
| Related citations | |
| 2. | Ann Dermatol Venereol. 2011;138(4):354-356. Epub 2010 Nov 24.[Histology of cutaneous leishmaniasis.][Article in French] Mokni M, Mebazaa A, Boubaker S.Service de dermatologie, hôpital La Rabta, rue Jabbari-Bab Saadoun, 1007 Tunis, Tunisie. |
| PMID: 21497266 [PubMed - as supplied by publisher] | |
| Related citations | |
| 3. | Int J Antimicrob Agents. 2011 Apr 14. [Epub ahead of print]Psilostachyin C: a natural compound with trypanocidal activity.Sülsen VP, Frank FM, Cazorla SI, Barrera P, Freixa B, Vila R, Sosa MA, Malchiodi EL, Muschietti LV, Martino VS.Cátedra de Farmacognosia, IQUIMEFA (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 (1113), Buenos Aires, Argentina. AbstractIn this study, the antiprotozoal activity of the sesquiterpene lactone psilostachyin C was investigated. This natural compound was isolated from Ambrosia scabra by bioassay-guided fractionation and was identified by spectroscopic techniques. Psilostachyin C exerted in vitro trypanocidal activity against Trypanosoma cruzi epimastigotes, trypomastigotes and amastigotes, with 50% inhibitory concentration (IC(50)) values of 0.6, 3.5 and 0.9μg/mL, respectively, and displayed less cytotoxicity against mammalian cells, with a 50% cytotoxic concentration (CC(50)) of 87.5μg/mL. Interestingly, this compound induced ultrastructural alterations, as seen by transmission electron microscopy, in which vacuolisation and a structural appearance resembling multivesicular bodies were observed even at a concentration as low as 0.2μg/mL. In an in vivo assay, a significant reduction in the number of circulating parasites was found in T. cruzi-infected mice treated with psilostachyin C for 5 days compared with untreated mice (7.4±1.2×10(5)parasites/mL vs. 12.8±2.0×10(5)parasites/mL) at the peak of parasitaemia. According to these results, psilostachyin C may be considered a promising template for the design of novel trypanocidal agents. In addition, psilostachyin C inhibited the growth of Leishmania mexicana and Leishmania amazonensis promastigotes (IC(50)=1.2μg/mL and 1.5μg/mL, respectively). Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. |
| PMID: 21497061 [PubMed - as supplied by publisher] | |
| Related citations | |
| 4. | J Vet Intern Med. 2011 Mar;25(2):398-9. doi: 10.1111/j.1939-1676.2010.0668.x. Epub 2011 Jan 31.Paraparesis caused by vertebral canal leishmaniotic granuloma in a dog.Cauduro A, Favole P, Lorenzo V, Simonetto L, Barda B, Cantile C, Asperio RM.Neurovet via Maestri del Lavoro 29 Legnano, Milano, Italy. alberto.cau@libero.it |
| PMID: 21281352 [PubMed - indexed for MEDLINE] | |
| Related citations | |
 |
| 5. | Bull Exp Biol Med. 2010 Nov;149(6):731-3.Effects of human defensin-α(1)on Trypanosoma cruzi trypomastigotes in vitro.Kleschenko YE, Karpenko LP, Villalta F.Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN, USA. AbstractHuman defensin-α(1)is a biologically active peptide exhibiting a dose-dependent trypanocidal effect in vitro against trypomastigotes and amastigotes of Trypanosoma cruzi line Tulahuen. This effect is determined by fragmentation of parasite DNA reducing the capacity of passaged T. cruzi to invade HeLa cells. |
| PMID: 21165432 [PubMed - indexed for MEDLINE] | |
| Related citations | |
 |
| 6. | Adv Exp Med Biol. 2011;691:221-30.TNF-α and TNFR in Chagas disease: from protective immunity to pathogenesis of chronic car diomyopathy.Lannes-Vieira J, Pereira IR, Vinagre NF, Arnez LE.Laboratory of Biology of the Interactions, Oswaldo Cruz Institute, Fiocruz, Av. Brasil 4365, Rio de Janeiro 21045-900, RJ, Brazil. lannes@ioc.fiocruz.br |
| PMID: 21153326 [PubMed - indexed for MEDLINE] | |
| Related citations | |
 |
| 7. | J Eukaryot Microbiol. 2011 Jan-Feb;58(1):7-10. doi: 10.1111/j.1550-7408.2010.00514.x. Epub 2010 Dec 3.A quantitative in vitro cultivation te chnique to determine cell number and growth rates in strains of Crithidia bombi (Trypanosomatidae), a parasite of bumblebees.Popp M, Lattorff HM.Institut für Biologie, Molekulare Ökologie, Martin-Luther-Universität Halle-Wittenberg, Hoher Weg 4, 06099 Halle, Saale, Germany. mario.popp@zoologie.uni-halle.de AbstractThe protozoan parasite Crithidia bombi and its host, the bumblebee Bombus terrestris, are used as a model system for the study of the evolutionary ecology of host-parasite interactions. In order to study these interactions we established a method for in vitro cultivation of single parasite strains. Additionally, a high-throughput method is developed for the determination of cell numbers in cultures by means of optical density (OD) measurements. The protocol for in vitro cultivation allowed for growing different strains on agar plates as well as in culture medium. A calibration curve for the relationship between cell number and OD has been developed. Subsequently, growth rates for different genotypes of C. bombi have been recorded. Significant differences in the growth rates and generation times between these genotypes were demonstrated. As this might be related to the virulence of the parasite, this relationship may be confirmed by in vivo growth rate determination. In comparison with conventional cell counting, the application of OD measurements allows for high-throughput experiments as the time taken to record each sample is reduced by a factor of 30. The in vitro cultivation method allows for controlled infection experiments in order to study host-parasite interactions. © 2010 The Author(s). Journal of Eukaryotic Microbiology © 2010 International Society of Protistologists. |
| PMID: 21129082 [PubMed - indexed for MEDLINE] | |
| Related citations | |
| |
| 8. | Curr Opin Infect Dis. 2010 Dec;23(6):609-16.Advances in Chagas disease drug development: 2009-2010.Buckner FS, Navabi N.Department of Medicine, Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, 98195, USA. fbuckner@u.washington.edu AbstractPURPOSE OF REVIEW: The need for better drugs to treat patients with Chagas disease remains urgent. This review summarizes the advancements in drug development over the past 2 years. RECENT FINDINGS: Drug development efforts are almost exclusively occurring as preclinical research, although phase II studies for the antifungal drug, posaconazole, and a prodrug of ravuconazole are being planned. Several recent laboratory investigations demonstrate anti-Trypanosoma cruzi activity of novel small molecules in animal models. These include nonpeptidic cruzain inhibitors, novel inhibitors of the sterol 14α-demethylase enzyme, new compounds (arylimidamides) related to pentamidine, derivatives of nifurtimox, compounds using ruthenium complexes, and several natural products. The recent implementation of a high-throughput screen of more than 300 000 compounds against intracellular T. cruzi amastigotes done at the Broad Institute is an important development, yielding approximately 300 selective inhibitors, many of which may serve as leads for medicinal chemistry efforts. SUMMARY: Progress is slow, but recent advancements in both drug development and advocacy for research on neglected diseases are encouraging. Efforts to define a target product profile and to harmonize methodologies for testing drugs for Chagas disease are described herein. |
| PMID: 20885320 [PubMed - indexed for MEDLINE] | |
| Related citations | |
 |
| 9. | Artif Intell Med. 2011 Jan;51(1):67-74. Epub 2010 Jul 14.A decision support system for Crithidia luciliae image classification.Soda P, Onofri L, Iannello G.Medical Informatics and Computer Science Laboratory, Integrated Research Centre, University Campus Bio-Medico of Rome, Via Alvaro del Portillo, 21, 00128 Rome, Italy. p.soda@unicampus.it AbstractOBJECTIVE: Systemic lupus erythematosus is a connective tissue disease affecting multiple organ systems and characterised by a chronic inflammatory process. It is considered a very serious sickness, further to be classified as an invalidating chronic disease. The recommended method for its detection is the indirect immunofluorescence (IIF) based on Crithidia Luciliae (CL) substrate. Hoverer, IIF is affected by several issues limiting tests reliability and reproducibility. Hence, an evident medical demand is the development of computer-aided diagnosis tools that can offer a support to physician decision. METHODS: In this paper we propose a system that classifies CL wells integrating information extracted from different images. It is based on three main decision phases. Two steps, named as threshold-based classification and single cells recognition, are applied for image classification. They minimise false negative and false positive classifications, respectively. Feature extraction and selection have been carried out to determine a compact set of descriptors to distinguish between positive and negative cells. The third step applies majority voting rule at well recognition level, enabling us to recover possible errors provided by previous phases. RESULTS: The system performance have been evaluated on an annotated database of IIF CL wells, composed of 63 wells for a total of 342 images and 1487 cells. Accuracy, sensitivity and specificity of image recognition step are 99.4%, 98.6% and 99.6%, respectively. At level of well recognition, accuracy, sensitivity and specificity are 98.4%, 93.3% and 100.0%, respectively. The system has been also validated in a daily routine fashion on 48 consecutive analyses of hospital outpatients and inpatients. The results show very good performance for well recognition (100% of accuracy, sensitivity and specificity), due to the integration of cells and images information. CONCLUSIONS: The described recognition system can be applied in daily routine in order to improve the reliability, standardisation and reproducibility of CL readings in IIF. Copyright © 2010 Elsevier B.V. All rights reserved. |
| PMID: 20630721 [PubMed - indexed for MEDLINE] | |
| Related citations | |
 |
No comments:
Post a Comment